New Biotech, Synaptix, launched to develop treatment for Tubb4a H-abc!

habcfoundationuk

Oct 15, 20211 min read

Very exciting news for the H-abc community. Biotech Synaptix has launched and are working hard to develop ASO gene therapy for H-abc and Tubb4a. Click on their website below to learn more.

www.synaptixbio.com

Recent Posts

See All

Addressing the Funding Crisis for Special Needs Education in the UK

Being a parent of a child suffering from Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC), a condition caused by...

Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story

BBC Interview Tubb4a Family

New Biotech, Synaptix, launched to develop treatment for Tubb4a H-abc!

Recent Posts

Comments

SIGN UP FOR OUR NEWSLETTER

Join our newsletter and we'll keep you up to date about all of our latest news, research and ways to get involved.

H-ABC FOUNDATION UK

GET IN TOUCH

amy@habcfoundationuk.co.uk